26. Naive patients without comorbidities
Use as first line assessment
+
or
Serum markers Transient elastography
Haute Autorite de Santé, 2008 EASL HCV Clinical Practice Guidelines J Hepatol 2011
28. Is diagnosing significant fibrosis
still important in the era of DAAs ?
?
F0 F1 F2 F3 F4
Indication for antiviral treatment
Boceprevir Telaprevir
29. Is diagnosing significant fibrosis
still important in the era of DAAs ?
?
F0 F1 F2 F3 F4
Indication for antiviral treatment
Clinical complications HVPG>10
Boceprevir Telaprevir
Significant risk of OV bleeding HVPG>12